---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-089277"
form_type: "8-K"
ticker: "SGHT"
cik: "0001531177"
company_name: "Sight Sciences, Inc."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:48:18.425677+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sight Sciences Q2 revenue $21.4M (-9% YoY); net loss $0.25/sh; FY guidance cut to $81M-$83M

## Summary
- Total revenue $21.4M (-9% YoY); net loss $12.3M ($0.25/sh) vs $14.8M loss in Q2 2023.
- Surgical Glaucoma revenue $20.2M (-5% YoY); Dry Eye revenue $1.1M (-46% YoY).
- Cash used improved to $9.1M from $12.8M in Q2 2023; cash and equivalents $118.2M.
- Narrowed FY2024 revenue guidance to $81M-$83M (0-2% growth) from prior $81M-$85M; adj. op. expenses $107M-$109M.
- CMS proposes device-intensive status for OMNI procedure, which could increase ASC facility fee 29% in 2025.

## SEC filing metadata
- accession: 0000950170-24-089277
- form_type: 8-K
- ticker: SGHT
- cik: 0001531177
- company_name: Sight Sciences, Inc.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1531177/000095017024089277/0000950170-24-089277-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1531177/000095017024089277/sght-20240801.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-089277
- JSON: https://secwatch.observer/filing/0000950170-24-089277.json
- Plain text: https://secwatch.observer/filing/0000950170-24-089277.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.